Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude Oil
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries
Regeneron Pharmaceuticals
(NQ:
REGN
)
1,179.31
+3.98 (+0.34%)
Streaming Delayed Price
Updated: 4:00 PM EDT, Aug 16, 2024
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Regeneron Pharmaceuticals
< Previous
1
2
...
20
21
22
23
24
25
26
27
28
...
38
39
Next >
Intellia Therapeutics Looks To Repeat Its Landmark Success In CRISPR Gene Editing
September 16, 2022
Intellia tested its CRISPR approach in cardiomyopathy and hereditary angioedema.
Via
Investor's Business Daily
Important Biotech Catalysts For September 15, 2022 - End Of The Day Summary
September 15, 2022
Via
Benzinga
Something Unusual Is Happening Right Now With Biotech Stocks Like Catalyst, Vertex, Neurocrine And BioMarin
September 15, 2022
The market is struggling, yet biotech stocks are acting like it's good times again. Here's why.
Via
Investor's Business Daily
Alnylam/Regeneron-Backed NASH Candidate Shows Encouraging Safety Profile In Healthy Volunteers
September 15, 2022
Via
Benzinga
Regeneron's Bispecific Antibodies Show Encouraging Anti Tumor Activity
September 12, 2022
Via
Benzinga
Analyst Ratings for Regeneron Pharmaceuticals
September 09, 2022
Within the last quarter, Regeneron Pharmaceuticals (NASDAQ:REGN) has observed the following analyst ratings:
Via
Benzinga
Regeneron Stock Soars On Pair Of Successful Trials
September 08, 2022
Studies "support aflibercept 8 mg as a potential new standard-of-care," the drugmaker said.
Via
Investor's Business Daily
US Department Of Health, Defense To Inject $1B To Boost Domestic Biomanufacturing
September 14, 2022
Via
Benzinga
ASLAN Pharma Starts Eblasakimab Program In Dupixent Treated Dermatitis Patients
September 14, 2022
Via
Benzinga
Biden Administration Pushes 'Cancer Moonshot' Initiative: Report
September 13, 2022
President Joe Biden channeled John F. Kennedy on the 60th anniversary of the former President's moonshot speech, highlighting the Biden administration's efforts to "end cancer as we know it." The...
Via
Benzinga
A Major October Catalyst Could Make This Eye Stock A Ten Bagger, Analyst Says
September 13, 2022
Chardan initiated coverage on Outlook Therapeutics Inc (NASDAQ: OTLK) with a Buy rati
Via
Benzinga
Why These 3 Stocks Are Off to Hot September Starts
September 13, 2022
Let’s look at what is behind the surprise rise in these three names—and whether they can continue to pace this month’s market rally.
Via
MarketBeat
Topics
Economy
Exposures
Economy
Interest Rates
9 Analysts Have This to Say About Regeneron Pharmaceuticals
September 09, 2022
Analysts have provided the following ratings for Regeneron Pharmaceuticals (NASDAQ:REGN) within the last quarter:
Via
Benzinga
Jefferies Upgrades Regeneron Pharmaceuticals: Here's What You Need To Know
September 09, 2022
Jefferies upgraded its rating of Regeneron Pharmaceuticals (NASDAQ:REGN) to Hold with a price target of $675.00, changing its price target from $536.00 to $675.00. Shares of Regeneron Pharmaceuticals...
Via
Benzinga
'Highly Compelling' Eye Drug Data Has Wall Street Stampeding To Buy This 'Large Cap Growth Story.' Even After $15B In Market Cap Was Added
September 09, 2022
Via
Benzinga
What 9 Analyst Ratings Have To Say About Regeneron Pharmaceuticals
September 09, 2022
Over the past 3 months, 9 analysts have published their opinion on Regeneron Pharmaceuticals (NASDAQ:REGN) stock. These analysts are typically employed by large Wall Street banks and tasked with...
Via
Benzinga
Benzinga's Top Ratings Upgrades, Downgrades For September 9, 2022
September 09, 2022
Upgrades
Via
Benzinga
Regeneron Pharmaceuticals To $851? Here Are 5 Other Price Target Changes For Friday
September 09, 2022
Morgan Stanley raised the price target on Regeneron Pharmaceuticals, Inc. (NASDAQ: REGN) from $625 to $851. Morgan Stanley analyst Matthew Harrison also upgraded the stock from Equal-Weight to...
Via
Benzinga
US Stock Futures Surge; Fed Speakers In Focus
September 09, 2022
Pre-open movers U.S. stock futures traded higher in early pre-market trade after recording gains on Thursday. The Dow Jones jumped around 193 points, while the Nasdaq Composite climbed 0.6% in the...
Via
Benzinga
Why ShiftPixy Surged Around 177%; Here Are 71 Biggest Movers From Yesterday
September 09, 2022
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares surged 176.5% to close at $31.00 on Thursday after the company announced plans to spin-off ShiftPixy Labs and dividend its digital securities to...
Via
Benzinga
Important Biotech Catalysts For September 8, 2022 - End Of The Day Summary
September 08, 2022
Via
Benzinga
Regeneron-Sanofi Eczema Drug Shows Improvements In Itchy Inflammatory Skin Disease
September 08, 2022
Via
Benzinga
Why Bilibili Is Trading Lower By Over Around 14%, Here Are 50 Stocks Moving In Thursday's Mid-Day Session
September 08, 2022
Gainers ShiftPixy, Inc. (NASDAQ: PIXY) shares jumped 73.8% to $19.48 after the company announced plans to spin-off ShiftPixy Labs and dividend its digital securities to shareholders.
Via
Benzinga
AeroVironment, Snap And Some Other Big Stocks Moving Higher On Thursday
September 08, 2022
U.S. stocks traded higher, with the Dow Jones gaining around 100 points on Thursday. Here are some big stocks recording gains in today’s session.
Via
Benzinga
Regeneron Gains As New Data Favors Higher Dose Of Flagship Eye Disease Drug
September 08, 2022
Via
Benzinga
Regeneron Pharmaceuticals Whale Trades For September 06
September 06, 2022
Someone with a lot of money to spend has taken a bullish stance on Regeneron Pharmaceuticals (NASDAQ:REGN). And retail traders should know. We noticed this today when the big position showed up on...
Via
Benzinga
Sanofi-Regeneron's Flagship Drug Shows Consistent Efficacy, Safety Profile At Two Years For Asthma In Kids
September 06, 2022
Via
Benzinga
If You Invested $100 In This Stock 20 Years Ago, You Would Have $3,900 Today
September 02, 2022
Regeneron Pharmaceuticals (NASDAQ:REGN) has outperformed the market over the past 20 years by 12.59% on an annualized basis producing an average annual return of 20.17%. Currently, Regeneron...
Via
Benzinga
What Are Whales Doing With Regeneron Pharmaceuticals
September 01, 2022
A whale with a lot of money to spend has taken a noticeably bullish stance on Regeneron Pharmaceuticals. Looking at options history for Regeneron Pharmaceuticals (NASDAQ:REGN) we detected 15 strange...
Via
Benzinga
Bluebird bio Seeks Back-to-Back Nods, 'Go' or 'No-Go' For Revance's Botox Rival, Amylyx' Twin Hurdles And More: September's Key PDUFA Catalysts Biotech Investors Must Know
August 31, 2022
After August’s mixed tally for Food and Drug Administration approvals, investors turn to a new month, which has a fairly loaded calendar.
Via
Benzinga
< Previous
1
2
...
20
21
22
23
24
25
26
27
28
...
38
39
Next >
Data & News supplied by
www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy
and
Terms and Conditions
.